A device inspired by woodpeckers and bighorn sheep has shown to help protect non-helmeted female athletes from traumatic brain injuries sustained over the course of a soccer season.
The Q-Collar is a device worn around the neck that presses lightly against the jugular vein, slowing blood outflow from the skull. That increased blood volume serves to stop the brain from sloshing during an impact. While the device’s effect has been studied before, particularly among helmeted sports such as men’s ice hockey and football, a newly-released study is the first to look at girls in non-helmeted sports. (Female athletes are, in general, more susceptible to brain injury.)
The Cincinnati Children’s Hospital and Q30 Innovations, the company behind the Q-Collar, studied its effects on a team of female high school soccer players during a competitive season. The results of the study, which have been published in the British Journal of Sports Medicine, revealed “no significant changes” in the brain’s white-matter from pre- to post-season of those athletes wearing the device, while those on the team who didn’t wear the collar displayed “significant white-matter changes” despite a similar number of head impacts.
“We were looking at female athletes because that is certainly an underserved population in terms of receiving research,” said Dr. Greg Myer, director of sports medicine research at Cincinnati Children’s and lead author of the study. “Female athletes tend to be more susceptible to a head impact. Our football studies showed that male athletes can have an average of 800 head impacts over 20G, while girls are closer to 150 impacts over 20G. It’s a substantial difference.”

#mc_embed_signup
/* Add your own MailChimp form style overrides in your site stylesheet or in this style block.
We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. */

Get the latest sports tech news in your inbox.

Over a six-month period, the researchers studied every head impact sustained during practice and games to get an understanding of how repetitive sub-concussive hits can change the white matter structure of the brain over the course of a season. The hits, which were tracked using accelerometers placed behind the left ear during practice and games, ranged from heading a ball to colliding with another player, or a hard fall. The study looked at 46 female high school players, 24 of who wore the Q-Collar. All the athletes underwent neuroimaging up to three times over the study, which spanned the course of a competitive season and a three-month wind-down period where they were at reduced risk of head impact.
The researcher’s overall conclusion matched that from Q30’s previous studies: Helmets alone aren’t the solution.
“In sports, there’s a heavy focus on single big blows to the head that might lead to what is subjectively described as a concussion,” said Myer. “What we really wanted to look at now is the cumulative effect of head impact exposure over an entire season. Evidence indicates that cumulative load of head impacts is potentially more concerning than that one single blow.”
The imaging conducted during the three-month postseason showed that white matter changes in the non-collar group either partially resolved or fully returned to normal. But the concern is that sustaining injuries such as these over time could weaken the brain and lead to more serious consequences.
A high school soccer player wears the Q-Collar and an accelerometer sensor. (Courtesy of Q30)
Myer views the study as sparking a “paradigm shift” in how people look at concussion prevention.
“Long-term blows are just as important as creating the perfect helmet,” he said. “To us, it doesn’t make a lot of sense to just look at concussions because that’s one hit of the 200 to 500 you could take during a season. We focused our studies on the cumulative load that the brain is exposed to. We want to reduce the burden of the brain in a sport where you could have head impacts.”
Q30 is working with the FDA to get the collar approved as a medical device and is using its nearly three-dozen medical studies conducted over the past six years as evidence to support its case. Last year, Q-Collar was approved as a medical device for commercial sale in Canada.
Tom Hoey, co-CEO of Q30, said the hope is that the Q-Collar sets a precedent for innovations claiming to protect the brain from concussions.
“Working with the FDA is absolutely critical, and we’re happy to be working with them,” said Hoey. “As a medical device, our marketing claims will have to be approved by the FDA before we can market the Q-Collar in the U.S. We believe that it would be a good thing if other products that claim to reduce traumatic brain injury had to go through the same rigor of the FDA process.”
Dr. David Smith, a co-author of the recent study, came up with the idea for the Q-Collar after researching head-ramming bighorn sheep and woodpeckers and analyzing how both animals routinely tolerate high-speed cranium collisions with no adverse impact.

Manchester United, the global soccer giant and perennial English Premier League contender, has renewed its partnership with Canon Medical Systems Europe. The company continues as the team’s official medical systems partner, and the sophisticated use of its imaging technology promises to offer the Red Devils a competitive advantage.
Canon, perhaps best known for its advanced photography equipment, acquired Toshiba Medical in 2016. Under terms of the initial partnership struck with Man U in 2013, Toshiba had installed advanced imaging technology—including CT, MRI, and ultrasound machines—at the club’s medical center at the Aon Training Complex. This new agreement includes an expansion of medical services, including more cardiac and general health screenings.
“During the past six years, our partnership has redefined the standard for medical imaging in elite sport,” said Dr. Steve McNally, Manchester United’s head of sports medicine and science, in a statement. “Daily access to state-of-the-art equipment and intelligent technologies has improved responsiveness to clinical presentations. Most importantly, we have developed a concept of ‘performance imaging’ over and above clinical diagnostics.
“By utilizing innovative techniques borne out of shared ideas and experiences from Canon Medical’s wider network of experts, we can now profile and monitor our players in ways we have never done before. This not only enhances athlete health and safety but also provides invaluable information to guide the athletic development process. As part of the partnership, we have also shared data that will assist in improving health services for the general public.”
SportTechie Takeaway
Manchester United’s 2018-19 payroll is said to be £137.3 million ($177.7 million), per Spotrac, so keeping players healthy is, of course, of great consequence. What’s unique here is McNally’s comment about “performance imaging.” The ability to improve physical development goes beyond medical assessments and taps a new frontier for this screening technology.

Genetic information will soon be a standard part of sports, used to customize training, personalize nutrition, and even to identify talent. Over the last few years, DNA analysis firm Athletigen and elite track and field training facility Altis have been working together to explore and develop that future.
Through collaboration, both Altis and Athletigen have been hoping to gain a head start in this race, learning what genetic information is important and how to convert that into actionable insights. A new product launched by Athletigen on Tuesday, the Altis Sport Performance Report, is hoping to bring some of what the two organizations have learned to consumers, both pro and amateur.
Altis’s athletes have been the lab rats that Athletigen can study, a population of highly fit individuals who closely follow training and nutrition protocols, generating accurate data that give context to the results from genetic testing. John Godina, a three-time Olympian who founded Altis in 2013, describes his organization as something between a training center and an educational and research institute. “[Altis] is a great science lab,” he said. “It gives us a chance to do stuff in a controlled environment that can benefit all kinds of different people.”
More than a dozen Altis-trained athletes competed at the Rio 2016 Olympic Games, including Canadian sprinter Andre de Grasse, who brought home silver from the 200m and bronze from both the 100m and 4x100m relay. Athletigen would not confirm which Altis athletes have been screened, citing privacy concerns, but the number reaches above 100. Through Altis’s apprentice coach program, Athletigen has also engaged with hundreds of coaches, and, by extension, may have impacted the training of thousands of athletes.
Akeem Haynes with his bronze medal. (Courtesy of Athletigen)
Akeem Haynes, a teammate of de Grasse both at Altis and in the 4x100m relay at Rio 2016, is quoted on Athletigen’s website about his experience with genetic testing. “Athletigen gave me different insight, gave me a slight edge … Anywhere an athlete can have a slight edge is huge.” (Haynes received financial support from Athletigen in the run up to the Games.)
When the sequencing of the human genome was completed in 2003, that effort had taken 13 years and cost $2.7 billion. Athletigen now charges $199 and takes four to six weeks to scan a person’s DNA for the different gene variants used in the Altis report. (The company scans for more than 850,000 gene variants, but the majority of these are not yet associated with athletic performance or ability.)
While Athletigen has previously offered athletes DNA-based advice, the new report is the first that is specifically tailored as a result of its work with Altis. The report offers information and advice based on more than 50 gene variants related to 22 different relevant traits, from fat metabolism to muscle growth, and caffeine sensitivity to error avoidance. Athletes are given information on how their gene variant might affect each trait, details on how common a variant is in the general population, an explanation of each gene’s role, and advice on how this knowledge could be used to adjust training, recovery, and nutrition. The aim of the report, according to CEO and cofounder Jeremy Koenig, has been to combine his company’s genetics knowledge with Atlis’s coaching experience and training recommendations.
Athletigen also includes a scientific confidence level for each trait. The highest confidence, A, requires the gene variant-to-trait association to have been tested in at least three independent studies of at least 1,000 individuals. One or more of those studies needs to have considered different ethnic groups.

Athletigen looks for genetic variations that are known as single nucleotide polymorphisms or SNPs (“snips”). These are changes in a single base—the DNA letters A, C, G, and T—at a specific location, but they can also indicate larger substitutions in sections of the surrounding code. An example is the rs1815739 SNP on the ACTN3 gene of chromosome 11. This gene encodes a protein called alpha-actinin-3, which is found only in fast-twitch muscle fibers. But when the usual C at the rs1815739 location is switched out with a T, production of the protein is disrupted, favoring slow-twitch fibers instead.
Theoretically, having the CC genotype, one letter for each of the relevant bases on the maternal and paternal copies of chromosome 11, should confer an advantage in power sports—that variant has become known as the “sprint gene.” But most people with the sprint gene are not sprinters, and not all sprinters have the sprint gene. Combining various studies together implies that as many as 25% of the US population could have that variant.
Those statistics create a problem for direct-to-consumer genetic testing in sports: the sprint gene seems to be neither essential to, nor predictive of, athletic destiny. In 2015, many of the sports-genetics research initiatives being run by universities around the globe were unified under the banner of the Athlome Project, an enterprise reminiscent of the idea that started this all, the Human Genome Project. The group of 24 leading researchers behind the Athlome Project published a consensus statement in the British Journal of Sports Medicine that November warning that “genetics tests have no role to play in talent identification or the individualised prescription of training to maximise performance.” A year later, the Australian Institute of Sport echoed that opinion in the same journal, and an article by Rebecca Robbins published on STAT in November 2016 warned of this growth of genetic testing in sports, expressing concern that the science might not yet back the claims companies are making.

#mc_embed_signup
/* Add your own MailChimp form style overrides in your site stylesheet or in this style block.
We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. */

Get the latest sports tech news in your inbox.

Genetic variants are only classified as SNPs if they occur within at least one percent of the population, “and everything that’s present in more than one percent of the population can’t be that bad,” explained Mikael Mattsson, an exercise physiologist and researcher in a genetics lab at Stanford University. (Mattsson was also a contributor to the BJSM consensus statement against genetic testing in sports.) “And if it can’t be that bad, it can’t be super good, either.” Each SNP might also only contribute a small amount to any one trait, so to accurately determine the genetic impact on that trait could require studying tens if not hundreds of relevant SNPs.
According to Eric Topol, a professor of genomics at the Scripps Research Institute in La Jolla, Calif., “We’ve jumped the gun by taking these soft markers and making too much out of them.” The problem, Topol explained, is that our ability to test for SNPs far outstrips our knowledge of their importance.

Coaches at Altis arrived at a similar conclusion to the BJSM consensus statement: There is virtually zero value in tests for variants of ACTN3. “We can look at the ACTN3 gene, and if you don’t have that, there’s nothing much we can do about it,” said Altis CEO Stuart McMillan. “So it’s not going to affect what we do in the least.”
Jeremy Koenig, who left a research job developing fertility screens at Performance Genomics to found Athletigen, emphasizes that his company has no interest in talent identification, and that sports genetics shouldn’t be about classifying gene variants as either good or bad. “You can’t really pass or fail a genetic test,” he explained.
Koenig calls DNA “our collective technology,” and lists the philosopher Alan Watts as one of his thought idols. “Things are as they are,” Watts once said. “Looking out into the universe at night, we make no comparisons between right and wrong stars, nor between well and badly arranged constellations.”
Athletigen DNA analysis kit. (Courtesy of Athletigen)
Koenig believes that the information extracted from Athletigen’s analysis can be empowering, whether or not it seems to show a genetic advantage or disadvantage. He is also careful to meter any expectations of what the results might hint at. “In some incidences we’re very confident [in the science], and in others it’s early days,” he said. “That comes back to the scientific process. Part of that scientific process is being transparent with the state of the research.”
“We’re certainly not in a space where dark chocolate and red wine are good for you one day, and the next day they’re not.”
Koenig ran track at Dalhousie University, competing in the 60m indoor sprint. He has also worked as a strength and conditioning coach, mostly with hockey players. Past clients have included former NHL players James Sheppard and Sean O’Donnell. Boston Bruins two-time All-Star Brad Marchand is quoted on Athletigen’s webpage. “In today’s NHL, simply working hard is not enough. Using Athletigen ensures that I am exhausting my efforts in the right direction. Knowing my genetics means that there is no wasted effort.”

Though Altis predominantly works with track and field athletes, Koenig sees the knowledge gained from the partnership as being relevant across all athletic disciplines. “Track and field is the foundation for all sports,” he explained.
At its core, Athletigen is a social technology company. The more athletes who sign up, the more powerful Athletigen’s database will become. Even the most ardent critics of direct-to-consumer sports genetics see huge potential in that. “In the future they might build their database and do the analysis from their data, which could be very beneficial,” Mattsson said.
“If we got the really extreme phenotype—top notch athletes—and we sequenced them,” Topol said, “we eventually will learn.”
Jeremy Koenig talks at an Altis apprentice coach program seminar. (Courtesy of Athletigen)
And Koenig emphasizes the partnership with coaches has become a key part of his company’s platform. According to Dan Pfaff, Altis’s head coach who has experience coaching athletes at 10 different Olympic Games, “Athletigen showed me how DNA can be used to help people achieve world-class performance.”
The new Altis report is designed to provide recommendations from Altis’s coaching staff based on insight on an athlete’s genetics gleaned from Athletigen’s analysis. For those who wish to know more, the report also includes videos of seminars from Altis’s apprenticeship coaching program. The aim, according to Koenig, is to combine genetics and coaching expertise without overwriting tried-and-true training methodologies. “[Not just] How do we get this into the hands of athletes,” Koenig said, “but how do we do it in a way that benefits them.”
As much as each athlete might be interested in his or her personal genetic score, Athletigen’s real product might be the community itself.

Outdoor equipment maker Mammut has launched a new climbing helmet that incorporates the multi-directional impact protection system, which is designed to reduce rotational forces during impact.
While there are a number of MIPS helmets on the market today, including bike and ski helmets that climbers have adapted to their sport, Swiss-based Mammut said its Wall Rider MIPS is the world’s first MIPS-integrated helmet targeted specifically at climbing.
“As one of the oldest and most respected outdoors brands in the world, Mammut has not forgotten its history as inventor of the climbing rope, revolutionizing the way that outdoors-people perform and achieve goals and successes through the centuries, and today,” the company said in a statement.

#mc_embed_signup
/* Add your own MailChimp form style overrides in your site stylesheet or in this style block.
We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. */

Get the latest sports tech news in your inbox.

MIPS is a patented technology located inside helmets that is designed to reduce rotational forces caused by certain impacts, in this case such as tumbling rocks or falls. Rotational acceleration has been found to be the predominant injury mechanism in concussion. The MIPS system consists of an internal layer flexibly attached to the external part of the helmet. When the Wall Rider MIPS is subjected to an angled impact, the external part of the helmet can then slide slightly relative to the head. A portion of the rotational forces and energies are therefore redirected and absorbed rather than being transferred to the brain.
Andres Lietha, head of hardware at Mammut Sports, said many of the company’s developers and product managers are climbers and mountain bikers.
“So we started to ask us the obvious question, how can we add the safety MIPS offers to climbers also?” he said in the press release. “We did in-depth research and found data showcasing that a significant part of head injuries in climbing also result from a rotational impact.”
The new Wall Rider, which clocks in at just 225 grams (0.5 pounds), will be available at Backcountry.com and Mammut.com starting on Oct. 4 for $179, followed by a launch at retailers nationwide on Feb. 1.
SportTechie Takeaway
MIPS is making its way through helmets involved in a host of sports and recreational activities (including bicycle helmets and ski helmets) amid the increased attention on traumatic brain injuries caused by inadequate head protection. A number of companies are investing heavily in helmet technology and developing proprietary materials and absorption technologies to try to mitigate the problem. Beyond MIPS, the National Football League has been leading the charge among the professional sports leagues by conducting studies on football-related head trauma and hosting startup challenges to crowdsource solutions. The MIPS tech addresses a specific kind of rotational impact that caters to falls off walls, bikes, or snow equipment.